TOP
Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients.
- Pubmed_id: 31781762
- Journal: The Journal of infectious diseases
-
Genbank_id: No known Genbank_id
- Date: Mar 2020
- Volume: 221
- Issue: 7
- Pages: 1117-1126
-
Author(s):
Douglas CM,
Barnard R,
Holder D,
Leavitt R,
Levitan D,
Maguire M,
Nickle D,
Teal V,
Wan H,
van Alewijk DCJG,
van Doorn LJ,
Chou S,
Strizki J,
- Abstract: The detected incidence of CMV resistance among subjects who received LET as prophylaxis in this Phase 3 trial was low. The LET RAVs that were detected mapped to the CMV UL56 gene at positions associated with reduced susceptibility to LET based on resistance selections in cell culture.
Interdeposit Digital Number: IDDN.FR.001.420004.000.S.X.2024.000.31230
